{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:41:53Z","timestamp":1791636113349,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115869","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T18:13:15Z","timestamp":1699639995000},"page":"115869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-2730","authenticated-orcid":false,"given":"Celia","family":"Casta\u00f1o-Amores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3963-6546","authenticated-orcid":false,"given":"Alba","family":"Ant\u00fanez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pozo-Agundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-239X","authenticated-orcid":false,"given":"Cristina Luc\u00eda","family":"D\u00e1vila-Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2023.115869_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.biopha.2023.115869_bib2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/clc.22471","article-title":"Effect of high-dose statin pretreatment on the incidence of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: grading the evidence through a cumulative meta-analysis","volume":"38","author":"Zhai","year":"2015","journal-title":"Clin. Cardiol."},{"issue":"14","key":"10.1016\/j.biopha.2023.115869_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FJC.0000000000000922","article-title":"Efficacy of long-term oral beta-blocker therapy in patients who underwent percutaneous coronary intervention for st-segment elevation myocardial infarction with preserved left ventricular ejection fraction: a systematic review and meta-analysis","volume":"77","author":"Maqsood","year":"2021","journal-title":"J. Cardiovasc Pharm."},{"key":"10.1016\/j.biopha.2023.115869_bib5","first-page":"249","article-title":"Chromosomal region 11p14.1 is associated with pharmacokinetics and pharmacodynamics of Bisoprolol","volume":"15","author":"Fontana","year":"2022","journal-title":"PharmgenomicsPers Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10741-008-9094-x","article-title":"Beta-blocker pharmacogenetics in heart failure","volume":"15","author":"Shin","year":"2010","journal-title":"Heart Fail Rev."},{"issue":"12","key":"10.1016\/j.biopha.2023.115869_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/clc.20981","article-title":"Differential effect of \u03b2-blockers for heart rate control in coronary artery disease","volume":"34","author":"Cordero","year":"2011","journal-title":"Clin. Cardiol."},{"issue":"16","key":"10.1016\/j.biopha.2023.115869_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013115","article-title":"Genome-wide meta-analysis of blood pressure response to \u03b21-blockers: results from ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)","volume":"8","author":"Singh","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"10.1016\/j.biopha.2023.115869_bib9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/jpm11111230","article-title":"PharmVIP: a web-based tool for pharmacogenomic variant analysis and interpretation","volume":"11","author":"Piriyapongsa","year":"2021","journal-title":"J. Pers. Med."},{"issue":"10","key":"10.1016\/j.biopha.2023.115869_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","article-title":"Pharmacogenetic factors affecting \u03b2-blocker metabolism and response","volume":"16","author":"Thomas","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2023.115869_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112069","article-title":"Pharmacogenetic polymorphisms affecting bisoprolol response","volume":"142","author":"Casta\u00f1o-Amores","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2013.193","article-title":"An investigation of CYP2D6 genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy","volume":"95","author":"Batty","year":"2014","journal-title":"Clin. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.115869_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00228-008-0525-3","article-title":"CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction","volume":"64","author":"Goryachkina","year":"2008","journal-title":"Eur. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2023.115869_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2014.62","article-title":"Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate","volume":"96","author":"Hamadeh","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib15","first-page":"341","article-title":"Ubiquitous pharmacogenomics consortium. implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium","volume":"101","author":"van der Wouden","year":"2017","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib16","first-page":"414","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2013.193","article-title":"An investigation of CYP2D6 genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy","volume":"95","author":"Batty","year":"2014","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.115869_bib18","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1177\/147323000803600624","article-title":"Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol","volume":"36","author":"Yuan","year":"2008","journal-title":"J. Int Med Res"},{"key":"10.1016\/j.biopha.2023.115869_bib19","series-title":"Medical Genetics Summaries [Internet]","article-title":"Carvedilol Therapy and CYP2D6 Genotype. 2018 Aug 1","author":"Dean","year":"2012"},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1248\/bpb.30.537","article-title":"Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis","volume":"30","author":"Yakekuma","year":"2007","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib21","first-page":"21","article-title":"Impact of the \u03b21-adrenoceptor Gly389Arg polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients","volume":"92","author":"Rau","year":"2012","journal-title":"Clin. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2023.115869_bib22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.sjbs.2020.06.022","article-title":"Bisoprolol responses (PK\/PD) in hypertensive patients: a cytochrome P450 (CYP) 2D6 targeted polymorphism study","volume":"27","author":"Mohammed Alkreathy","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1515\/dmpt-2018-0015","article-title":"Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking \u03b2BBs in the Republic of Sakha (YAKUTIA)","volume":"33","author":"Fedorinov","year":"2018","journal-title":"Drug Metab. Pers. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib24","first-page":"372","article-title":"Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol","volume":"74","author":"Liu","year":"2003","journal-title":"Clin. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib25","first-page":"44","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib26","first-page":"366","article-title":"A common beta1-adrenergic receptor polymorphism (Gly389Arg) affects blood pressure response to beta-blockade","volume":"73","author":"Sofowora","year":"2003","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clpt.2004.10.006","article-title":"Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release\/extended release in heart failure","volume":"77","author":"Terra","year":"2005","journal-title":"Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01213011-200503000-00001","article-title":"Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure","volume":"15","author":"de Groote","year":"2005","journal-title":"Pharm. Genom."},{"issue":"9","key":"10.1016\/j.biopha.2023.115869_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1440-1681.2012.05736.x","article-title":"Effect of the Gly389Arg \u03b2\u2081-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment","volume":"39","author":"Petersen","year":"2012","journal-title":"Clin. Exp. Pharm. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.anes.0000267530.62344.a4","volume":"107","author":"Zaugg","year":"2007","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115869_bib31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.2008.139","article-title":"INVEST Investigators. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension","volume":"84","author":"Pacanowski","year":"2008","journal-title":"Clin. Pharm. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2023.115869_bib32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jcph.1443","article-title":"\u03b22 -Adrenergic receptor gene affects the heart rate response of BBs: evidence From 3 clinical studies","volume":"59","author":"Shahin","year":"2019","journal-title":"J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2023.115869_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00008571-200307000-00002","article-title":"Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure","volume":"13","author":"Kaye","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"6","key":"10.1016\/j.biopha.2023.115869_bib34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/pgs.11.20","article-title":"Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics","volume":"12","author":"Sehrt","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.biopha.2023.115869_bib35","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jama.294.12.1526","article-title":"Beta2-adrenergic receptor genotype and survival among patients receiving BB therapy after an acute coronary syndrome","volume":"294","author":"Lanfear","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.biopha.2023.115869_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3904\/kjim.2015.043","article-title":"Impact of the \u03b2-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between \u03b2 adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study","volume":"31","author":"Lee","year":"2016","journal-title":"Korean J. Intern Med"},{"issue":"5","key":"10.1016\/j.biopha.2023.115869_bib37","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/FPC.0b013e328338e1b8","article-title":"Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment","volume":"20","author":"Suonsyrj\u00e4","year":"2010","journal-title":"Pharm. Genom."},{"issue":"11","key":"10.1016\/j.biopha.2023.115869_bib38","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jacc.2005.08.041","article-title":"The Gly389Arg beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity","volume":"46","author":"Bruck","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib39","first-page":"414","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115869_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.dib.2016.12.019","article-title":"The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent","volume":"10","author":"D\u00e1vila-Fajardo","year":"2016","journal-title":"Data Brief."},{"key":"10.1016\/j.biopha.2023.115869_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent","volume":"225","author":"S\u00e1nchez-Ramos","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1021055617738","article-title":"DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping","volume":"33","author":"Freeman","year":"2003","journal-title":"Behav. Genet"},{"key":"10.1016\/j.biopha.2023.115869_bib43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.chemosphere.2015.07.079","article-title":"Polymorphisms of pesticide-metabolizing genes in children living in intensive farming communities","volume":"139","author":"G\u00f3mez-Mart\u00edn","year":"2015","journal-title":"Chemosphere"},{"key":"10.1016\/j.biopha.2023.115869_bib44","unstructured":"How does KASP work. LGC Biosearch Technologies. Disponible en: \u3008https:\/\/www.biosearchtech.com\/support\/education\/kasp-genotyping-reagents\/how-does-kasp-work\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2007.07.002","article-title":"Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses","volume":"117","author":"Brodde","year":"2008","journal-title":"Pharm. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2023.115869_bib47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/pgs-2019-0056","article-title":"The importance and challenges of developing a pharmacogenetics test for hypertension","volume":"20","author":"Snyder","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/pgs-2018-0191","article-title":"The future of pharmacogenetics in the treatment of hypertension","volume":"20","author":"Cunningham","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.biopha.2023.115869_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-018-0058-6","article-title":"ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to \u03b2-blockers in patients with heart failure","volume":"4","author":"Huang","year":"2018","journal-title":"Cell Discov."},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2010.315","article-title":"Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions","volume":"89","author":"Johnson","year":"2011","journal-title":"Clin. Pharm. Ther."},{"issue":"32","key":"10.1016\/j.biopha.2023.115869_bib51","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1021\/bi00198a006","article-title":"Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties","volume":"33","author":"Green","year":"1994","journal-title":"Biochemistry"},{"issue":"Pt 1","key":"10.1016\/j.biopha.2023.115869_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1113\/jphysiol.2005.098558","article-title":"Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with differences in cardiovascular function at rest and during exercise in humans","volume":"571","author":"Snyder","year":"2006","journal-title":"J. Physiol."},{"issue":"25","key":"10.1016\/j.biopha.2023.115869_bib53","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1161\/CIRCULATIONAHA.104.519652","article-title":"Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years","volume":"111","author":"Masuo","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2023.115869_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/pgs.09.158","article-title":"Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension","volume":"11","author":"Filigheddu","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10557-010-6220-5","article-title":"Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure","volume":"24","author":"Metra","year":"2010","journal-title":"Cardiovasc Drugs Ther."},{"issue":"4","key":"10.1016\/j.biopha.2023.115869_bib56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(03)00044-8","article-title":"MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study","volume":"5","author":"White","year":"2003","journal-title":"Eur. J. Heart Fail"},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2008.172","article-title":"Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users","volume":"85","author":"Bijl","year":"2009","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115869_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.683498","article-title":"Influence of CYP2D6 and CYP3A5 polymorphisms on the pharmacokinetics and pharmacodynamics of bisoprolol in hypertensive chinese patients","volume":"8","author":"Chan","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2023.115869_bib59","unstructured":"The Pharmacogenomic Knowledge Base (PharmGKB). Annotation of DPWG Guideline for bisoprolol and CYP2D6 [Internet]. Stanford. [Citado el 18 de julio de 2023]. Recuperado a partir de: bisoprolol (pharmgkb.org)."},{"issue":"2","key":"10.1016\/j.biopha.2023.115869_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2014.62","article-title":"Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate","volume":"96","author":"Hamadeh","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.115869_bib61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","article-title":"Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension","volume":"76","author":"Zineh","year":"2004","journal-title":"Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2023.115869_bib62","first-page":"116","article-title":"The need of a multicomponent guiding approach to personalize clopidogrel treatment","volume":"21","author":"Valeria","year":"2021","journal-title":"Pharm. J."},{"issue":"1","key":"10.1016\/j.biopha.2023.115869_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1074248415581175","article-title":"Influence of different \u03b2-blockers on platelet aggregation in patients with coronary artery disease on dual antiplatelet therapy","volume":"21","author":"Ignjatovic","year":"2016","journal-title":"J. Cardiovasc. Pharm. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:13:31Z","timestamp":1777576411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223016670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":63,"alternative-id":["S0753332223016670"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115869","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115869"}}